Abstract
Lung cancer is still the leading cause of cancer related death worldwide. Fibroblast growth factor receptor (FGFR) is a tirosine-kinase receptor that is seen to be amplified or mutated in non-small cell lung cancer (NSCLC) and it plays a crucial role in tumour development and maintenance.
The authors analyzed the state of the art of FGFR by reviewing the current literature. Fibroblast growth factor (FGF)-FGFR pathway and their aberrations are described, with the evaluation of their possible prognostic role in NSCLC and in particular in squamous cell carcinomas, in which FGFR is more often amplified. New therapeutic agents targeting FGFR signaling have been developed and are now in clinical evaluation.
Dysregulation of FGF signaling in tumour cells is related to FGFR gene amplification or mutation, although it is still uncertain which of these aberrations represents a real predictor of response to specific inhibitors. However, recent evidence has questioned whether FGFR is a real target in squamous cell histology. The effectiveness of FGFR inhibitors is also still unclear since there are no clinical data on selected patients. Moreover, the management of specific side effects related to inhibition of the physiological role of FGF should be more thorough.
Keywords: fifbroblast growth factor receptor (FGFR), non-small-cell lung cancer (NSCLC), amplification, tumorigenic role, prognostic role, targeted inhibitors.
Anti-Cancer Agents in Medicinal Chemistry
Title:Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Volume: 16 Issue: 9
Author(s): Federica Biello, Giovanni Burrafato, Erika Rijavec, Carlo Genova, Giulia Barletta, Anna Truini, Simona Coco, Maria Giovanna Dal Bello, Angela Alama, Francesco Boccardo and Francesco Grossi
Affiliation:
Keywords: fifbroblast growth factor receptor (FGFR), non-small-cell lung cancer (NSCLC), amplification, tumorigenic role, prognostic role, targeted inhibitors.
Abstract: Lung cancer is still the leading cause of cancer related death worldwide. Fibroblast growth factor receptor (FGFR) is a tirosine-kinase receptor that is seen to be amplified or mutated in non-small cell lung cancer (NSCLC) and it plays a crucial role in tumour development and maintenance.
The authors analyzed the state of the art of FGFR by reviewing the current literature. Fibroblast growth factor (FGF)-FGFR pathway and their aberrations are described, with the evaluation of their possible prognostic role in NSCLC and in particular in squamous cell carcinomas, in which FGFR is more often amplified. New therapeutic agents targeting FGFR signaling have been developed and are now in clinical evaluation.
Dysregulation of FGF signaling in tumour cells is related to FGFR gene amplification or mutation, although it is still uncertain which of these aberrations represents a real predictor of response to specific inhibitors. However, recent evidence has questioned whether FGFR is a real target in squamous cell histology. The effectiveness of FGFR inhibitors is also still unclear since there are no clinical data on selected patients. Moreover, the management of specific side effects related to inhibition of the physiological role of FGF should be more thorough.
Export Options
About this article
Cite this article as:
Biello Federica, Burrafato Giovanni, Rijavec Erika, Genova Carlo, Barletta Giulia, Truini Anna, Coco Simona, Bello Giovanna Dal Maria, Alama Angela, Boccardo Francesco and Grossi Francesco, Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (9) . https://dx.doi.org/10.2174/1871520616666160204112347
DOI https://dx.doi.org/10.2174/1871520616666160204112347 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of New Drugs for COPD
Current Medicinal Chemistry Hsp90 Inhibition with Resorcylic Acid Lactones (RALs)
Current Topics in Medicinal Chemistry Gene Therapy (Part I)
Current Gene Therapy The Cellular Uptake and Apoptotic Efficiency of Colchicine is Correlated with Downregulation of MMP-9 mRNA Expression in SW480 Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets Molecular Markers of Angiogenesis and Metastasis in Lines of Oral Carcinoma after Treatment with Melatonin
Anti-Cancer Agents in Medicinal Chemistry Cystic Fibrosis, Vector-Mediated Gene Therapy, and Relevance of Toll-Like Receptors: A Review of Problems, Progress, and Possibilities
Current Gene Therapy Discovery of Hybrid Purine-quinoline Molecules and Their Cytotoxic Evaluation
Letters in Drug Design & Discovery Image Fusion Based on Estimation Theory: Applied to PET/CT for Radiotherapy
Recent Patents on Medical Imaging Towards the Management of Inflammation: Recent Developments of mPGES-1 Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) Anti-Cancer Natural Product Library from Traditional Chinese Medicine
Combinatorial Chemistry & High Throughput Screening Aryl- and Heteroaryl-Thiosemicarbazone Derivatives and Their Metal Complexes: A Pharmacological Template
Recent Patents on Anti-Cancer Drug Discovery Disposition of Pharmacologically Active Dietary Isoflavones in Biological Systems
Current Drug Metabolism Spirooxindoles as Potential Pharmacophores
Mini-Reviews in Medicinal Chemistry A Review of the Treatment Strategies for Small Cell Lung Carcinoma Patients with a Poor Performance Status
Current Respiratory Medicine Reviews Regulation of Angiogenesis by Th1- and Th2-Type Cytokines
Current Pharmaceutical Design A Comprehensive Review on Perfusion Method Development for Bone Marrow Collection and Stem Cell Transplantation
Current Stem Cell Research & Therapy Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety Synthesis, Biological Evaluation and Molecular Dynamics Simulation Studies of Novel Diphenyl Ethers
Medicinal Chemistry Supramolecular Approaches for Drug Development
Current Medicinal Chemistry